Filing Flows › Collegium Pharmaceutical (COLL) › Gross margin
Collegium Pharmaceutical (COLL) gross margin by quarter
Collegium Pharmaceutical's gross margin was 58.0% in Q3 2026 (third quarter 2026), -2.6 pts from Q1 2026. Over the last 6 quarters it ranged from 54.8% (Q1 2025) to 62.5% (Q4 2025).
| Quarter | Gross margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 58.0% | -2.6 pts | -3.7 pts |
| Q1 2026 | 60.6% | -1.9 pts | +5.8 pts |
| Q4 2025 | 62.5% | +0.8 pts | — |
| Q3 2025 | 61.7% | +4.0 pts | — |
| Q2 2025 | 57.7% | +2.9 pts | — |
| Q1 2025 | 54.8% | — | — |
Q3 2026 at a glance
Collegium Pharmaceutical, Q3 2026: revenue $216M (+3% year over year), operating margin 13.3%, net earnings $21.8M, operating cash flow $86.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Collegium Pharmaceutical's gross margin?
Collegium Pharmaceutical's gross margin was 58.0% in Q3 2026 (third quarter 2026), -2.6 pts from Q1 2026.
How has Collegium Pharmaceutical's gross margin changed?
Over the last 6 quarters it ranged from 54.8% (Q1 2025) to 62.5% (Q4 2025).
Q3 2026 results → · How Collegium Pharmaceutical makes money →